Can Gene Therapy Deliver Durability? - Summary - MDSpire
Conference News

Can Gene Therapy Deliver Durability?

At Retina World Congress, David A. Eichenbaum, MD, examined whether late-stage intravitreal gene therapies can reduce injection burden in nAMD.

  • By

  • Jim Gallagher, senior managing editor

  • May 14, 2026

  • 5 min

Share

At the 2026 Retina World Congress, Dr. David A. Eichenbaum addressed the potential of intravitreal gene therapies to alleviate the burden of injections in patients with neovascular age-related macular degeneration (nAMD). With a focus on durability, he highlighted data from phase 3 programs indicating that gene therapies like ixoberogene soroparvovec (Ixo-vec) show sustained intraocular anti-VEGF expression, leading to better management of visual acuity and reduced need for supplemental injections. Safety remains a primary consideration as these therapies progress toward broader clinical applications.

Original Source(s)

Can Gene Therapy Deliver Durability?

  • by Jim Gallagher, senior managing editor

  • May 14, 2026

Related Content

Music May Ease Anxiety in Eye Clinics

Background music and multimedia exposure were associated with lower patient-reported anxiety in a quasi-experimental ophthalmology clinic study that used existing clinic audiovisual infrastructure at no additional cost.

Smoking Doubles Risk of Vision Loss

New research indicates smoking doubles the risk of multiple sight-threatening conditions

  • May 15, 2026

  • 3 min
FDA Updates: Retina Trials and Regulatory Pathways

William M. Boyd, MD, director of the FDA’s Division of Ophthalmology, discussed the agency’s evolving approaches to clinical evidence, trial design, and expedited regulatory pathways at the 2026 Retina World Congress meeting.